top of page

Browse by category

Search

Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide

Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide

Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide

Novo Nordisk is planning a study that will see CagriSema, a new investigational medicine developed by Novo that combines Cagrilintide and...

Once-daily oral nonpeptide GLP-1-RA achieved up to 14.7% mean weight reduction at 36 weeks

Once-daily oral nonpeptide GLP-1-RA achieved up to 14.7% mean weight reduction at 36 weeks

Once-daily oral nonpeptide GLP-1-RA achieved up to 14.7% mean weight reduction at 36 weeks

Phase 2 data for orforglipron (12 mg, 24 mg, 36 mg or 45 mg), a nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, has...

SURMOUNT-1: Tirzepatide results in 22.5% weight loss in adults with obesity or overweight

SURMOUNT-1: Tirzepatide results in 22.5% weight loss in adults with obesity or overweight

SURMOUNT-1: Tirzepatide results in 22.5% weight loss in adults with obesity or overweight

Tirzepatide (5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli...

MBS improved hypertension outcomes, lowering use of antihypertensive medications

2 days ago

Bariatric surgery associated with improved IBD outcomes

2 days ago

FDA accepts Rhythm’s sNDA for setmelanotide in acquired hypothalamic obesity

3 days ago

Back to Top

bottom of page